Repository logo
Log in(current)
Repository logoMIT Open ScholarshipDSpace@MIT
  1. Home
  2. MIT Open Access Articles
  3. MIT Open Access Articles
  4. EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma

EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma

Thumbnail Image
Download
Name

nihms935677.pdf

Size

2.15 MB

Format

Adobe PDF

Checksum (MD5)

e0eee91bb1e977bf6c229c0c7876cd8f

Download all files submitted through automated deposit
sword-2019-03-15.original.zip (1.54 MB)
Author(s)
Iniguez, Amanda Balboni
•
Stolte, Björn
•
Wang, Emily Jue
•
Conway, Amy Saur
•
Alexe, Gabriela
•
Dharia, Neekesh V.
•
Kwiatkowski, Nicholas
•
Zhang, Tinghu
•
Abraham, Brian J.
•
Mora, Jaume
more
Date Issued
February 2018
Journal
Cancer Cell
Publisher
Elsevier BV
Citation
Iniguez, Amanda Balboni, Björn Stolte, Emily Jue Wang, Amy Saur Conway, Gabriela Alexe, Neekesh V. Dharia, Nicholas Kwiatkowski, et al. “EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma.” Cancer Cell 33, no. 2 (February 2018): 202–216.e6. © 2017 Elsevier Inc.
Version
Final published version
Abstract
Many cancer types are driven by oncogenic transcription factors that have been difficult to drug. Transcriptional inhibitors, however, may offer inroads into targeting these cancers. Through chemical genomics screening, we identified that Ewing sarcoma is a disease with preferential sensitivity to THZ1, a covalent small-molecule CDK7/12/13 inhibitor. The selective CDK12/13 inhibitor, THZ531, impairs DNA damage repair in an EWS/FLI-dependent manner, supporting a synthetic lethal relationship between response to THZ1/THZ531 and EWS/FLI expression. The combination of these molecules with PARP inhibitors showed striking synergy in cell viability and DNA damage assays in vitro and in multiple models of Ewing sarcoma, including a PDX, in vivo without hematopoietic toxicity. Iniguez et al. find that inhibition of CDK12 is synthetic lethal with EWS/FLI expression. CDK12/13 inhibitors impair DNA damage repair in cells expressing EWS/FLI, and the combination of CDK12/13 and PARP inhibitors synergistically reduces tumor growth and extends survival in Ewing sarcoma mouse models.
MIT Department
Massachusetts Institute of Technology. Department of Biology
Whitehead Institute for Biomedical Research
Terms of Use
Creative Commons Attribution-NonCommercial-NoDerivs License
http://creativecommons.org/licenses/by-nc-nd/4.0/
Persistent DSpace Link
http://hdl.handle.net/1721.1/121107
DOI of Published Version
https://doi.org/10.1016/J.CCELL.2017.12.009
Repository logo
PrivacyPermissionsAccessibilityContact us
Repository logo
Notify us about copyright concerns.